Cirrhosis, Liver Clinical Trial
Official title:
Acute-On-Chronic Liver Failure In Cirrhotic Patients In Sohag University Hospital
Cirrhosis is a condition characterized by diffuse fibrosis, severe disruption of the intrahepatic arterial and venous flow, portal hypertension and, ultimately, liver cell failure. Traditionally, cirrhosis has been dichotomised in compensated and decompensated, and the transition to decompensated cirrhosis happens when any of the following hallmarks occurs: presence of ascites, variceal haemorrhage and/ or hepatic encephalopathy (HE) . In Egypt, HCV is the main cause of liver cirrhosis followed by HBV
Cirrhosis is a condition characterized by diffuse fibrosis, severe disruption of the intrahepatic arterial and venous flow, portal hypertension and, ultimately, liver cell failure. Traditionally, cirrhosis has been dichotomised in compensated and decompensated, and the transition to decompensated cirrhosis happens when any of the following hallmarks occurs: presence of ascites, variceal haemorrhage and/ or hepatic encephalopathy (HE). In Egypt, HCV is the main cause of liver cirrhosis followed by HBV. Once cirrhosis transitions from the compensated to the decompensated stage, it is associated with short-term survival (3-5 years) . The concept of acute-on-chronic liver failure (ACLF) has been widely used to study patients who underwent artificial support therapies as a bridge to liver transplantation (LT). In 2009, the Asian Pacific Association for the Study of the Liver (APASL) provided the first consensus on ACLF, defined as "an acute hepatic insult manifesting as jaundice and coagulopathy, complicated within 4 weeks by ascites and/or encephalopathy". In 2014, the definition was further expanded to include 'high 28-day mortality'. Therefore, acute on top of chronic liver failure (ACLF) is defined as a syndrome characterized by acute decompensated cirrhosis associated with failure of various organs and high short term mortality rate; based on CANONIC study which is a large scale prospective study, in which the kidneys were the most common affected organs, followed by liver, coagulation, the brain, circulation and the lungs. ACLF can occur in patients with chronic liver disease without cirrhosis (type A), with compensated cirrhosis (type B), and with decompensated cirrhosis (type C) .In many cases, a precipitating factor linked to the development of ACLF can be identified including alcohol intake, reactivation of HBV or acute hepatitis due to HAV or HEV, bacterial infection or GI hemorrhage. The CLIF-C OF score which consists of numbers and types of organ failures (OFs) including kidneys, liver, coagulation, the brain, circulation, and the lungs is associated with 28-day and 90-day mortality. Moreover, some specific organ dysfunction such as kidney dysfunction and moderate HE, when associated with single OF, was also associated with bad prognosis . On this background, diagnostic criteria of ACLF were established according to the presence, type and number of OFs. The severity of ACLF was graded into different stages according to the number of OFs on ACLF grade 1, grade 2 and grade 3 and mortality correlates with ACLF severity. To predict prognosis and mortality more accurately. developed CLIF-C-ACLF score which has a greater prognostic capability than CLIF-C- OF, It consists of the CLIF-C- OF combined with age and WBCs count. Few studies have addressed the patterns of acute on chronic liver failure in Egyptian cirrhotic patients . Therefore, we will conduct our study to shed ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05793983 -
S100A8/A9 and Innate Immunity in Liver Disease
|
||
Completed |
NCT04604860 -
Use of EL-FIT App to Promote Physical Activity
|
N/A | |
Recruiting |
NCT05928624 -
A Pilot Trial to Test the Feasibility of Utilizing Home Blood Pressure Monitoring to Optimize the Administration of Midodrine Among Decompensated Cirrhosis Patients
|
N/A | |
Active, not recruiting |
NCT01438970 -
Effects of Treatment of Ascites by the ALFApump System on Renal and Circulatory Function
|
Phase 2 | |
Recruiting |
NCT05998330 -
LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease
|
N/A | |
Completed |
NCT04581369 -
Cirrhosis Medical Home
|
N/A | |
Withdrawn |
NCT04244877 -
Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility
|
Phase 3 | |
Recruiting |
NCT04588077 -
Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
|
Phase 4 | |
Recruiting |
NCT05538962 -
Longitudinal Monitoring of Inflammation in Cirrhosis
|
N/A | |
Completed |
NCT04082780 -
Rifamycin in Minimal Hepatic Encephalopathy
|
Phase 2 | |
Completed |
NCT03850977 -
Is There an Association Between Chronic Pancreatitis and Pulmonary Function
|
||
Active, not recruiting |
NCT03736265 -
Carvedilol for Prevention of Esophageal Varices Progression
|
N/A | |
Recruiting |
NCT04530760 -
Intraabdominal Hypertension and Occurrence of Microaspiration in Cirrhotics Under Mechanical Ventilation
|
||
Recruiting |
NCT05093218 -
Effect of Branch Chain Amino Acid Therapy on Sarcopenia in Children With Chronic Liver Disease.
|
N/A | |
Recruiting |
NCT03437876 -
Study on Effect of Intestinal Microbiota Transplantation in Hepatitis B Virus Induced Cirrhosis
|
N/A | |
Recruiting |
NCT05604274 -
Longitudinal Monitoring of Stool Characteristics
|
||
Recruiting |
NCT04867954 -
Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
|
||
Completed |
NCT04643795 -
Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
|
Phase 1 | |
Active, not recruiting |
NCT02344680 -
Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
|
||
Completed |
NCT04121520 -
Perioperative Care of HVPG Measurement (CHESS1904): An International Multicenter Survey
|